• Designed and implemented IP strategy for 13 FDA-approved drugs and 60 active clinical trials

Erleada, Imbruvica, Lesinurad, Maralixibat, neffy, Otiprio, Palsonify, Talazoparib, TEPEZZA, Tyrvaya, VIZZ, Widaplik, and Xiidra

• Extensive experience representing clients on both sell-side and buy-side M&As, with eight over $1 billion

Abide Therapeutics, Amplyx Pharmaceuticals, Aragon Pharmaceuticals, Ardea Biosciences, Horizon Therapeutics, Lengo Therapeutics, Pharmacyclics, RayzeBio, Seragon Pharmaceuticals, Synthorx, and Vividion Therapeutics, each leading to an acquisition by a major pharmaceutical company.

• Extensive experience representing underwriters, investors, and companies in financings
  

  Avalon BioVentures, AXA Investment Managers, Foresite Capital, Frazier Healthcare Partners, General Atlantic Service Company, Novo Holdings, OrbiMed, RA Capital Management, SR One Capital Management, venBio Partners, Vida Ventures, and other venture and investment funds, in IP diligence matters.

  Have supported more than 500 clients undergoing IP diligence for a venture round of investment

  Ambrx, ARS Pharma, Avidity Biosciences, Boundless Bio, Centessa Pharmaceuticals, Crinetics Pharmaceuticals, Denali Therapeutics, Design Therapeutics, Erasca, Harpoon Therapeutics, Janux Therapeutics, Kinnate Biopharma, LENZ Therapeutics, MBX Biosciences, ORIC Pharmaceuticals, Synthorx, and TCR2, all on IP matters related to their IPOs.

• Connects Life Sciences Community
  

  Co-creator of Wilson Sonsini’s Healthcare Investment Initiative, which includes the Healthcare Investment Forum and the Innovator’s Edge Series. Also on the board of directors for LaunchBio, and co-creator and host of the NextGen VC Podcast.